AURIGENE TO SEPARATE ITS DISCOVERY SERVICES BUSINESS

Aurigene is in the process of separating its Discovery Services Business. More details of the same will be shared in the near future.

The proprietary pipeline comprises:

Anti-inflammatory

RORγt (Phase II initiated)

Immuno-oncology: several first-in-class small molecule inhibitors

CD47

TIM3

TIGIT-PD-L1 dual

CD73-A2AR dual

Transcription inhibitors and precision oncology

PRMT5

CBP/p300

Targeted protein degradation for oncology

BET

SMARCA 2/4

CBP/p300

Anti-infective

FabI

 

For additional details contact partnering@aurigene.com